- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
April 14, 2023 updated by: Masonic Cancer Center, University of Minnesota
Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation).
followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).
Study Overview
Status
Recruiting
Conditions
- Lymphoma
- Follicular Lymphoma
- Acute Myeloid Leukemia
- Multiple Myeloma
- Myelofibrosis
- Juvenile Myelomonocytic Leukemia
- Burkitt Lymphoma
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Chronic Lymphocytic Leukemia
- Lymphoplasmacytic Lymphoma
- Acute Leukemia
- Mantle-Cell Lymphoma
- Chronic Myelogenous Leukemia
- Prolymphocytic Leukemia
- Myelodysplasia
- Plasma Cell Leukemia
- Small Lymphocytic Lymphoma
- Marginal Zone B-Cell Lymphoma
- Myeloproliferative Neoplasms
- Refractory Anemia
- High Risk Anemia
- Diffuse Large Cell Non Hodgkins Lymphoma
- High Grade Non-Hodgkin's Lymphoma, Adult
- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
- MRD Positive Leukemia
- Natural Killer Cell Malignancies
- Acquired Bone Marrow Failure Syndromes
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
300
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tamy Grainger
- Phone Number: (612)-273-2800
- Email: tgraing1@fairview.org
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55337
- Recruiting
- Masonic Cancer Center at University of Minnesota
-
Contact:
- Tamy Grainger, RN
- Phone Number: 612-273-2800
- Email: tgraing1@fairview.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 60 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
-Inclusion Criteria:
- Age: ≤ 60 years of age
- Performance Status: Karnofsky ≥ 70%, Lansky play score ≥ 70
- Consent: Voluntary written consent (adult or legally authorized representative; or parental/guardian)
Adequate Organ Function:
- Renal: Creatinine <2x upper limit of normal. Patients above this limit must have creatinine clearance ≥ 40 ml/min/1.73m2 as determined by an age-appropriate method, such as cystatin C GFR.
- Hepatic: Bilirubin, AST, alkaline phosphatase <4 times the upper limit of institutional normal
- Pulmonary: Diffusion capacity of oxygen, corrected for hemoglobin, > 50% of predicted. For pediatric patients not able to undergo PFTs or diffusion testing: O2 sat of >95% on room air
- Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 45%. For children not able to cooperate with MUGA or echocardiography, such should be clearly stated in the physician's documentation
- HIV Status: HIV infection with undetectable viral load. All HIV+ patients must be evaluated by Infectious Disease (ID) and a HIV management plan establish prior to transplantation
Other Inclusion Criteria:
- Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment.
- Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program
- Eligible Diseases and Status: Patients are eligible unless their treatment is to be guided by a higher priority protocol.
- Acute Leukemias: Must be in remission by morphology (≤5% blasts). Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse.
- Acute Myeloid Leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in ≤ 60 years old that is NOT considered as favorable-risk.
Favorable risk AML is defined as having one of the following:
- t(8,21) without cKIT mutation
- inv(16) or t(16;16) without cKIT mutation
- Normal karyotype with mutated NPM1 and wild type FLT-ITD
- Normal karyotype with double mutated CEBPA
- Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation
- Very high risk pediatric patients with AML: Patients <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy.
- Acute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL.
High risk ALL is defined as having one of the following:
- Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1
- 30 years of age or older at diagnosis
- White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis
- CNS leukemia involvement during the course of disease
- Slow cytologic response (>10% lymphoblasts in bone marrow on Day 14 of induction therapy)
- Evidence of persistent immonophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapy
- Very high risk pediatric patients with ALL: patients <21 years are also considered high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction or M3 marrow at the end of induction. They are eligible once they achieve a complete remission.
- Chronic Myelogenous Leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to one or more tyrosine kinase inhibitors.
- Plasma Cell Leukemia after initial therapy, in patients who have achieved at least a partial remission
- Myeloproliferative Neoplasms/Myelofibrosis, either primary as a result of polycythemia vera or essential thrombocythemia, with disease risk of intermediate or high-risk according to DIPSS criteria. Blasts must be <10% by bone marrow aspirate morphology.
- Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features. Blasts must be < 10% by a representative bone marrow aspirate morphology.
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone B-Cell Lymphoma or Follicular Lymphoma are eligible if there was disease progression/relapse within 12 of achieving a partial or complete remission. Patients who had remissions lasting > 12 months, are eligible after at least two prior therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be considered for debulking chemotherapy before transplant.
- Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy in CR1+ or PR1+.
- Diffuse large Cell NHL > CR/> PR: Patients in CR/PR with initial short remission (<6 months) are eligible, or those who have failed/or are not eligible for autologous transplant.
- Lymphoblastic Lymphoma, Burkitt's Lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year.
- Multiple Myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or β-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapy.
- Juvenile myelomonocytic leukemia
- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR.
- MRD positive leukemia (AML, ALL or accelerated/blast phase CML). Selected patients in morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD negative status.
- Natural Killer Cell Malignancies
- Acquired Bone Marrow Failure Syndromes except for Fanconi Anemia or Dyskeratosis Congenita
- Other Leukemia Subtypes: A major effort in the field of hematology is to identify patients who are of high risk for treatment failure so that patients can be appropriately stratified to either more (or less) intensive therapy. This effort is continually ongoing and retrospective studies identify new disease features or characteristics that are associated with treatment outcomes. Therefore, if new features are identified after the writing of this protocol, patients can be enrolled with the approval of two members of the study committee.
Exclusion Criteria:
- Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after > 2 salvage regimens)
- CML in blast crisis
- Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on salvage therapy.
- Evidence of progressive disease by imaging modalities or biopsy - persistent PET activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of CT changes indicating progression.
- Active central nervous system malignancy
- if ≤ 18 years old, prior myeloablative transplant within the last 6 months. If >18 years old prior myeloablative allotransplant or autologous transplant
- Active HIV infection or known HIV positive serology
- active uncontrolled infection
- Pregnant or breastfeeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TBI Regimen
|
Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
Other Names:
|
Experimental: Non-TBI Regimen
|
Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chronic GVHD - 1 year
Time Frame: 1 year
|
Incidence of chronic GVHD
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Grade II-IV acute GVHD
Time Frame: Day +100
|
Cumulative incidence grade II-IV acute GVHD
|
Day +100
|
Chronic GVHD - 2 years
Time Frame: 2 years
|
Incidence of chronic GVHD
|
2 years
|
Relapse
Time Frame: 2 years
|
Cumulative incidence of relapse
|
2 years
|
Overall survival
Time Frame: 2 years
|
Cumulative incidence of overall survival
|
2 years
|
Treatment-related mortality
Time Frame: 2 years
|
Cumulative incidence of treatment-related mortality
|
2 years
|
Graft-versus-host disease-free, relapse free survival (GRFS)
Time Frame: 1 year
|
Cumulative incidence of GRFS
|
1 year
|
Graft-versus-host disease-free, relapse free survival (GRFS)
Time Frame: 2 years
|
Cumulative incidence of GRFS
|
2 years
|
Neutrophil Engraftment
Time Frame: Day 42
|
Cumulative incidence of Neutrophil Engraftment
|
Day 42
|
Neutrophil Engraftment
Time Frame: 6 months
|
Cumulative incidence of Neutrophil Engraftment
|
6 months
|
Platelet Engraftment
Time Frame: Day 42
|
Cumulative incidence of Platelet Engraftment
|
Day 42
|
Platelet Engraftment
Time Frame: 6 months
|
Cumulative incidence of Platelet Engraftment
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shernan Holtan, MD, Masonic Cancer Center, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 30, 2018
Primary Completion (Anticipated)
January 10, 2025
Study Completion (Anticipated)
November 10, 2025
Study Registration Dates
First Submitted
October 16, 2017
First Submitted That Met QC Criteria
October 16, 2017
First Posted (Actual)
October 19, 2017
Study Record Updates
Last Update Posted (Actual)
April 18, 2023
Last Update Submitted That Met QC Criteria
April 14, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Virus Diseases
- Infections
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- DNA Virus Infections
- Tumor Virus Infections
- Neoplasms, Plasma Cell
- Myelodysplastic-Myeloproliferative Diseases
- Leukemia, Lymphoid
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Leukemia, B-Cell
- Lymphoma, B-Cell
- Myelodysplastic Syndromes
- Lymphoma
- Multiple Myeloma
- Leukemia
- Leukemia, Myeloid
- Lymphoma, Non-Hodgkin
- Leukemia, Myelomonocytic, Juvenile
- Burkitt Lymphoma
- Lymphoma, Mantle-Cell
- Lymphoma, B-Cell, Marginal Zone
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Waldenstrom Macroglobulinemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Anemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Myeloproliferative Disorders
- Leukemia, Prolymphocytic
- Leukemia, Plasma Cell
- Bone Marrow Failure Disorders
- Pancytopenia
- Anemia, Refractory
Other Study ID Numbers
- 2015LS034
- MT2015-29 (Other Identifier: University of Minnesota)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
University of WashingtonAstraZenecaRecruitingB-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...United States
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Epizyme, Inc.CompletedFollicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal LymphomaUnited Kingdom
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalVarian Medical SystemsNot yet recruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
Clinical Trials on HSCT with TBI Regimen
-
Children's Hospital Los AngelesRecruitingB-cell Acute Lymphoblastic LeukemiaUnited States
-
The First Affiliated Hospital of Soochow UniversityThe Second People's Hospital of Huai'anRecruiting
-
Kiadis PharmaCompletedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic SyndromeCanada, Belgium, Germany, Croatia, United Kingdom, Portugal
-
Nanfang Hospital, Southern Medical UniversityZhujiang HospitalCompletedAcute Myeloid Leukemia | Risk Stratification
-
General Hospital of Ningxia Medical UniversityUnknownTraumatic Brain Injury With Brief Loss of ConsciousnessChina
-
National Institute of Blood and Marrow Transplant...UnknownAplastic Anemia IdiopathicPakistan
-
Clinique Romande de ReadaptationActive, not recruitingTBI (Traumatic Brain Injury)Switzerland
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruitingAllogeneic Hematopoietic Stem Cell Transplantation | Central Nervous System LeukemiaChina
-
Massachusetts General HospitalSpaulding Rehabilitation HospitalCompletedTraumatic Brain Injury | Major Depressive DisorderUnited States
-
University of the PhilippinesCalmoseptine, Inc.CompletedIncontinence Associated DermatitisPhilippines